Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment

Blinatumomab is a bispecific T cell engager that has shown efficacy in relapsed/refractory Philadelphia chromosome (Ph)-positive and Ph-negative acute lymphoblastic leukemia (ALL). Considering its favorable safety and activity in advanced ALL, blinatumomab as a targeted immunotherapy is fast gaining...

Descripción completa

Detalles Bibliográficos
Autores principales: Pourhassan, Hoda, Agrawal, Vaibhav, Pullarkat, Vinod, Aldoss, Ibrahim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470626/
https://www.ncbi.nlm.nih.gov/pubmed/37664035
http://dx.doi.org/10.3389/fonc.2023.1237031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470626/
https://www.ncbi.nlm.nih.gov/pubmed/37664035
http://dx.doi.org/10.3389/fonc.2023.1237031

Ejemplares similares